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Background: Deregulated Notch signaling is linked to a variety of tumors and it is therefore important to learn
more about the frequency and distribution of Notch mutations in a tumor context.
Methods: In this report, we use data from the recently developed Cancer Cell Line Encyclopedia to assess the
frequency and distribution of Notch mutations in a large panel of cancer cell lines in silico.
Results: Our results show that the mutation frequency of Notch receptor and ligand genes is at par with that for
established oncogenes and higher than for a set of house-keeping genes. Mutations were found across all four
Notch receptor genes, but with notable differences between protein domains, mutations were for example more
prevalent in the regions encoding the LNR and PEST domains in the Notch intracellular domain. Furthermore, an
in silico estimation of functional impact showed that deleterious mutations cluster to the ligand-binding and the
intracellular domains of NOTCH1. For most cell line groups, the mutation frequency of Notch genes is higher than
in associated primary tumors.
Conclusions: Our results shed new light on the spectrum of Notch mutations after in vitro culturing of tumor cells.
The higher mutation frequency in tumor cell lines indicates that Notch mutations are associated with a growth
advantage in vitro, and thus may be considered to be driver mutations in a tumor cell line context.
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Our understanding of the molecular basis for cancer is
rapidly improving, to a large extent owing to the recent
progress in DNA sequencing technologies, which now al-
lows the mutational landscape to be explored in a
genome-wide manner both in primary tumors and in
tumor cell lines [1]. Thanks to these efforts, it is becoming
increasingly apparent that there are a small number of
very frequently mutated genes, along with a longer “tail”
of genes with fewer mutations. A recent insight is also that
tumors are endowed with specific sets of mutational sig-
natures that shed light on their history, both with regard
to internal processes such as defective DNA repair, but
also reflecting external processes, such as exposure of cells
to ultraviolet light or tobacco smoking [2]. By analyzing
the distribution of mutations in individual mutated genes,
oncogenes and tumor suppressor genes can increasingly* Correspondence: urban.lendahl@ki.se
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that are driver mutations, i.e. a mutation that confers a
growth advantage for the tumor, and passenger mutations,
i.e. mutations bringing no selective advantage to the
tumor, is rapidly improving. It is an emerging view that a
relatively limited set of evolutionarily conserved signaling
pathways harbor the majority of driver mutations and this
list includes for example the PI3K, MAPK, Hedgehog and,
important for this study, the Notch signaling pathway [1].
However, the relationship between a particular signaling
pathway and tumor development is still rather unex-
plored, and better insights into the mutational spectrum
will be important for understanding how deregulation of a
signaling pathway contributes to cancer and, in the long-
term, for future therapy development.
To gain further insights into the link between Notch
signaling and tumor development, we have analyzed the
extent of Notch mutations in tumor cell lines, using in-
formation from the recently published Cancer Cell Line
Encyclopedia (CCLE), which contains deep genomics andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with pharmacological profiles for a range of cancer thera-
peutics [3]. Notch signaling is a highly conserved cell-cell
interaction mechanism with a relatively simple molecular
architecture but a diverse, cell context-specific, signaling
output [4,5]. Notch signaling is initiated when a trans-
membrane Notch receptor is activated by transmembrane
ligands, of the Jagged or Delta-like type, on neighboring
cells. Ligand activation of the Notch receptor leads to pro-
teolytic cleavage of the receptor and release of its intracel-
lular domain (Notch ICD). Notch ICD relocates from the
membrane to the nucleus and binds to the DNA-binding
protein CSL (also referred to as RBP-Jκ or CBF1), leading
to activation of Notch downstream genes [5,6].
There are a number of links between deregulated Notch
signaling and cancer. Direct mutations or copy number
variations are observed in acute lymphoblastic T-cell
leukemia (T-ALL), non-small cell lung cancer (NSCLC)
and, to a lesser extent, breast cancer [7-9]. Furthermore,
deregulation of Notch signaling is observed in a broad
range of tumors. For example, in breast cancer, increased
Notch signaling, in the form of high Jagged1 expression, is
frequently observed [10,11]. On the other hand, and in
keeping with the cell context-dependent signaling output,
Notch can also act as a tumor suppressor gene. In the
skin, Notch signaling promotes, rather than blocks, differ-
entiation [12] and in line with this, Notch mutations in
squamous cell carcinoma (SCC) are usually inactivating
[13-15]. With these multiple links to cancer, it is not sur-
prising that development of Notch therapies is a very ac-
tive research area and although there are yet no clinically
approved therapies, there are ongoing clinical trials for a
number of indications [6].
In this report, we ask a number of questions regarding
the frequency of Notch mutations in tumor cell lines
and primary tumors: How frequent are Notch mutations
in tumor cell lines as compared to other well-established
oncogenes and house-keeping genes? How are mutations
distributed across the various Notch receptors? Is there
a preference for particular mutations in specific tumor
cell line types? Our data indicate that Notch mutations
occur at a frequency that suggests that they may confer
growth advantage during in vitro culture, i.e. that they
would be driver mutations, and we also identify receptor-
specific patterns of mutations. Information regarding the
spectrum of mutations to Notch receptors in cancer cell
line models can be a valuable resource for future Notch
research and may aid in the development of Notch tar-
geted therapies in cancer.
Methods
The CCLE dataset was downloaded from the CCLE-
database (http://www.broadinstitute.org/ccle). The dataset
was generated using a hybrid capturing assay togetherwith massively parallel sequencing and contains a list of
mutation and indels in 1651 genes across 905 cancer cell
lines, aligned to the human genome assembly hg19, where
the following variants had been filtered out: common
polymorphisms, allelic fractions below 10%, putative neu-
tral variants and mutations located outside the coding
DNA sequence. Mutations in introns, a (CTG)n-Notch4
polymorphism in exon 1 [16], non-synonomous mutations
and cell types having less than 5 cell lines were also
filtered out. The cell type barcodes “haematopoietic_
and_lymphoid_tissue” and “skin” that are used in the
CCLE-dataset are referred to as “blood” and “melanoma”,
respectively, throughout this manuscript.
Datasets kept on the cBioPortal server were used for
computing mutational frequencies in primary tumors,
utilizing the CGDS-R package in R (http://www.R-project.
org) [17,18]. The following datasets were utilized for the
analyses (totaling more than 2900 tumors; the sizes of the
data sets used are indicated in parenthesis): Endometrial
cancer (n = 248) [19], prostate cancer (n = 112) [20], large
intestine (n = 224) [21], esophageal cancer (n = 146) [22],
lung cancer (n = 230) [23], glioblastoma (n = 291) [24],
ovarian cancer (n = 316) [25], skin cancer (n = 121) [26],
liver cancer (n = 231) [27], pancreatic cancer (n = 99) [28],
breast cancer (n = 507) [29] and renal cancer (n = 424)
[30]. The study was conducted in accordance with the eth-
ical guide lines from the Central Ethical Review Board in
Sweden, as of June 1, 2008.
The CGDS-R package was utilized to explore putative
copy number alterations of Notch receptor genes in the
CCLE data set. The Cbioportal MutationMapper online
tool (http://www.cbioportal.org/public-portal/mutation_
mapper.jsp) was used for generating supplementary muta-
tion distribution plots. All other analyses were performed
using R. In Figure 2E, the SCC cell lines used in the ana-
lysis are: BICR56, TE11, OE21, TE8, KYSE270, KYSE180
and KYSE450.
Calculation of mutation frequency
The mutation frequency was calculated as the number
of mutations in a specific gene or gene family across all
cell lines or across a specific cell type. The CCLE classi-
fication of cell lines into different cell types, as specified
in the CCLE-dataset, was used. When determining mu-
tation frequencies for gene families with multiple genes
(e.g. Notch 1–4 or H/K/N-Ras), maximum one mutation
per cell line was counted. When determining the relative
distributions of mutational types in Figure 1D and Notch
receptors in Figure 1E, all mutations were taken into ac-
count. The Protein ANalysis THrough Evolutionary Rela-
tionships (PANTHER; http://www.pantherdb.org/) online
cSNP tool was used to estimate the impact of missense
































































































































































































































































































































































































































































































































Figure 1 (See legend on next page.)
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Figure 1 Notch components are frequently mutated in established cancer cell lines. (A-B) Overall mutation frequency (percentage mutated cell
lines) of NOTCH receptors 1–4, as well as of the three Ras proteins (H/K/N-Ras), ErbB1-4, p53, Patched1-2 and APC, as indicated. In (B), the mutation
frequencies are relative to the average coding region size (%/kbp). (C) Mutation frequency of Notch receptors and ligands. (D-E) Mutation frequency
of NOTCH receptors 1–4 in cell lines that have been clustered into specific cell types, as indicated. In (D), the relative distribution of the different types
of NOTCH receptor mutations is plotted for each cell type. In (E), the relative distribution of mutations in each NOTCH receptor is plotted for each cell
type. The number (#) of cell lines for each cell type is specified in (E). Indels = Insertions or deletions (not causing frame shift alterations). Frame Shift
Alt = Frame Shift Alterations. bp = base pairs. In (A-C), the mutation frequency for the corresponding gene/genes is indicated above each bar.
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The mutation frequency of Notch receptors and ligands
compared to other oncogenes and tumor suppressor
genes
In CCLE, more than 1,600 genes, including most known
oncogenes and tumor suppressor genes, have been se-
quenced across more than 900 human tumor cell lines
[3]. CCLE is therefore an ideal resource to explore muta-
tion patterns and frequencies in a large scale. To gain
new insights into Notch mutations, we first asked how
the frequency of Notch mutations compared to the mu-
tation frequencies in other well-established oncogenes
(H, K and N (H/K/N) Ras and ErbB1-4) and tumor sup-
pressor genes (p53, APC and Patched1-2). The mutation
frequency for p53 was highest (60.0%), followed by the
combined score for H/K/N Ras genes (26.4%), ErbB
genes (21.8%), NOTCH1-4 (20.4%), APC (15.5%) and
Patched1-2 (10.5%) (Figure 1A). Since a larger coding re-
gion on average is more prone to accumulating muta-
tions, we also recalculated the data in Figure 1A relative
to the size of the coding regions. This reveals that the
p53 and Ras family showed considerably higher muta-
tion frequencies than the other genes, but the Notch
mutation frequency was in the same range as for the
ErbB1-4, Patched1-2 and APC genes (Figure 1B). The
high scores for p53 and Ras likely reflect the exceptional
selective advantage of mutations in these two genes for
tumor growth and during in vitro establishment of cell
line cultures. When the four different Notch receptors
and four of the ligands (JAG1, JAG2, DLL1 and DLL4)
were analyzed individually, we found that the mutation
frequency for the genes ranged from 7.3% (NOTCH1) to
2.9% (DLL4) (Figure 1C).
We next asked whether the frequency of Notch recep-
tor gene mutations differed in cell lines derived from dif-
ferent tumor types. The data show that the mutation
frequency was highest in cell lines from endometrial,
prostate and large intestine tumors (Figure 1D), which
also were the cell types that harbored most mutations
overall (Additional file 1: Figure S1A). Cell lines from
the oesophagus and urinary tract showed a somewhat
lower mutation frequency, but in all cases higher than
25% (Figure 1D). At the other end of the spectrum, a
much lower Notch mutation frequency was noted in
tumor cell lines from mesothelioma (pleura), breast andkidney (less than 10%), and with no mutations in tumors
from the biliary tract (Figure 1D). 5.0 % of the cell lines
carried more than one mutation in NOTCH1-4 (data
not shown).
We next analyzed what types of Notch receptor gene
mutations were most prevalent in the tumor cell lines.
Across all tumor types, missense mutations were by far
the most dominant category, with a smaller proportion
of frame shift alterations and nonsense mutations and
with only a very small proportion of indels (insertions/
deletions) (Figure 1D). While Notch is a tumor suppres-
sor gene in skin [13-15], we did not find any nonsense
mutations in tumor cell lines derived from melanomas.
Finally, we assessed whether mutations in a specific
Notch receptor gene were associated with a particular
tumor cell line type. In the majority of the tumor cell
line types, mutations were found in at least three different
Notch receptor genes, but with liver as a notable excep-
tion, where only NOTCH1 and NOTCH4 were found to
be mutated (Figure 1E).
The distribution of mutations in the four Notch receptor
genes
The CCLE data set also allowed us to analyze the distri-
bution of mutations across the four different Notch re-
ceptor genes, to learn whether there are mutational
hotspots or whether a particular type of mutation associ-
ates with a particular receptor. Mutations were largely
scattered along the length of the receptors (Figure 2, left
hand side; Additional file 1: Figure S1 B-E), with one ex-
ception: a frame shift alteration in NOTCH3 clustered at
amino acid position 1802 (Figure 2C; Additional file 1:
Figure S1D). Missense mutations were the most com-
mon form of mutations for all Notch receptor types,
followed by frame shift alterations for NOTCH1-3; how-
ever, this class of mutations was not present to the same
extent in NOTCH4 (Figure 2; Additional file 1: Figure S1F).
More than 50% of the mutations resided in the EGF repeat
region of each receptor (NOTCH1 = 51.3%, NOTCH2 =
59.72%, NOTCH3 = 58.5% and NOTCH4 = 66.0%). Mis-
sense mutations involving a cysteine residue (either gain
or loss) in the EGF repeats is a hallmark for CADASIL
mutations in NOTCH3 [33], but we did not find any mis-
sense mutations affecting cysteine residues in the CCLE
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Figure 2 (See legend on next page.)
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Figure 2 Notch receptor mutation spectra for different cancer cell types. (A-E, left side) Mutation spectra for NOTCH1 (A,E), NOTCH2 (B), NOTCH3
(C) and NOTCH4 (D). (A-D, right side) Cell types ordered after mutation frequency for the corresponding Notch receptor. The Notch receptor domains
are listed in (A). In (E), previously described mutational hotspots in T-ALL and SCC are marked. LNR = Lin12-Notch repeats, HD = heterodimerization
domain, NRR = negative regulatory region, RAM = RBPJκ associated module, ANK = ankyrin repeats, PEST = proline, glutamic acid, serine and threonine
rich domain. Indels = Insertions or deletions, Frame Shift Alt = Frame Shift Alterations. Upper aero. tract = Upper aerodigestive tract. Autonomic g. =
autonomic ganglia. CNS = central nervous system. The different types of mutations are described at the bottom of the figure. Only mutations in the
coding region of the Notch receptor proteins are shown.
Mutvei et al. BMC Cancer  (2015) 15:311 Page 6 of 11most common form of mutation in Notch ligands
(Additional file 1: Figure S2).
Gain-of-function mutations in T-ALL, NSCLC and
breast cancer cluster in the negative regulatory region
(NRR) and PEST domains (Figure 2E) [7-9,34], and we
therefore analyzed whether mutations were more preva-
lent in these regions and whether they differed between
different receptors. PEST domain mutations were fre-
quently observed in NOTCH1, and two mutations were
found in NOTCH2, whereas there were no such muta-
tions in NOTCH3 and NOTCH4 (Figure 2A-D). For the
NRR region, which encompasses the LNR region and
heterodimerization domain (HD), we found a mutation
spectrum similar to the PEST domain, i.e. only a few
mutations were found in NOTCH3 or NOTCH4, whereas
21.1% of the NOTCH1 mutations and 12.2% of the
NOTCH2 mutations resided in this region (Figure 2A-D).
Prostate was the most frequently mutated cell type for
both NOTCH1 and NOTCH2 but prostate tumor cell
lines did not contain any mutations in NOTCH3 or
NOTCH4 (Figure 2A-D, right hand side). To learn more
about the differences in the mutational pattern between
skin and leukemias, which harbor gain- and loss-of-
function Notch mutations, respectively [7,12], we derived
the NOTCH1 mutational pattern from blood cell lines, in-
cluding T-ALL, and compared with cell lines derived from
melanoma and SCC. Approximately half of the mutations
from blood cell lines were found in the NRR and PEST
domains, in contrast to melanoma and SCC, where only
one mutation were found in these two domains (12.5%;
Figure 2E).
To explore the potential functional impact of the
Notch receptor mutations, we scored all missense muta-
tions for NOTCH1-4 with subPSEC (substitution pos-
ition-specific evolutionary conservation), using the
Protein ANalysis THrough Evolutionary Relationships
(PANTHER) cSNP tool. The subPSEC score is an esti-
mate of the likelihood for a given non-synonymous mu-
tation to functionally impact on the protein, ranging
from 0 (neutral) to −10 (the highest likelihood to be
deleterious), and a subPSEC score below −3 is regarded
as a cutoff for functional significance [31,32]. 47 of the
215 missense mutations in NOTCH1-4 (~22%) were esti-
mated to have a deleterious effect on the proteins, i.e. with
a score between −3 and −10. Interestingly, the mutationswith a subPSEC below −3 clustered in the ankyrin domain
and, for NOTCH1, in EGF repeats 11 and 15, a portion of
the receptor containing the ligand-binding domain
[35,36], as well as in the ICD (Figure 3A; Additional file 2:
Data 1).
Finally, since Notch receptors have been reported to be
amplified in ovarian cancers [37], we investigated if the
Notch receptors were subjected to copy number alter-
ations in cell lines. We utilized the CGDS-R cBioPortal
package for R to obtain data on putative copy-number al-
terations, which have been computed using the GISTIC2
algorithm [17,18,38]. Between 1.7% and 4.2% of all cell
lines had Notch high level amplifications, Notch4 being
the most frequently amplified (Figure 3B). Deletions were
less common for all Notch receptors, ranging from 0.6%
to 2.3% (Figure 3B).
The frequency of Notch mutations in tumor cell lines as
compared to primary tumors
Next, we compared the Notch mutation frequency in
tumor cell lines with the frequency observed in primary
tumors for the corresponding organs, using several data
sets kept on the cBioPortal server, the majority derived
from The Cancer Genome Atlas (TCGA). We reasoned
that this could serve as an estimate of whether muta-
tions accumulate over time during the culturing of
tumor cell lines, which in turn may indicate whether
such mutations offer a growth advantage in vitro. To
better relate Notch to other gene categories, we com-
pared mutation frequencies for Notch components to
the set of oncogenes and tumor suppressor genes used
in Figure 1A-B (p53, H/K/N Ras, APC, Patched1-2 and
ErbB1-4) as well as to a set of house-keeping genes that
have not been reported to be involved in tumor forma-
tion: polyadenylate-binding nuclear protein1 (PABPN1),
fucose-1-phosphate guanylyltransferase (FPGT) and Non-
POU domain-containing octamer-binding protein (NONO)
[39]. PABN1 encodes a protein involved in mRNA polya-
denylation [40], FPGT encodes a metabolic enzyme [41]
and the RNA-binding protein NONO was recently impli-
cated in the regulation of the circadian clock [42].
Notch mutation frequencies were found to be higher
in tumor cell lines than in primary tumors for all cell
types except for lung, which had the same frequency,
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Figure 3 Copy-number alterations and estimation of the impact of missense mutations on Notch1-4 receptor function using PANTHER cSNP.
(A) Schematic illustrations of the NOTCH1-4 receptors, showing the distribution of missense mutations with a subPSEC score lower than −3, i.e.
50% chance to be deleterious. The abbreviations for the Notch receptor domains are explained in the legend of Figure 2. (B) The distribution of
deletions and amplifications in the four Notch receptors is shown, with the percentage written to the right of the corresponding bar.
Mutvei et al. BMC Cancer  (2015) 15:311 Page 7 of 11in primary tumors (Figure 4A). The largest differences
in frequency were observed for the endometrium and
prostate cell types (Figure 4A) which however also had
the largest accumulation of mutations in vitro overall
(Additional file 1: Figure S1A). A similar increase in mu-
tation frequency in tumor cell lines was found in the
majority of cell types for APC, p53, Patched1-2 and ErbB1-
4 (Figure 4B,D,E,I; Additional file 1: Figure S3A,D,E). H/
K/N Ras, on the other hand, showed a more complex pat-
tern with an increase in endometrium ovary, liver, large
intestine and breast, but not in the other tumor types(Figure 4C). Notch ligands (JAG1-2, DLL1,4), like Notch
receptors, showed higher mutations frequencies in tumor
cell lines, although these were mainly restricted to the
endometrium and prostate cell types (Additional file 1:
Figure S3B,C). In contrast, mutation frequencies were
overall very low for the house-keeping genes, with lower
frequencies in tumor cell lines compared to primary
tumors across almost all cell types (Figure 4F,G,H,I;
Additional file 1: Figure S3D-E). In sum, these data sug-
gest that tumor cell lines generally contain a higher
































































































































































































































































































































































































































































































































































Cell type ranked by ∆% 
1 2 3 4 5 6 7 8 9 10 11 12
I
NOTCH1-4



















Figure 4 (See legend on next page.)
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Figure 4 Notch receptors constitute mutational hot spots in cancer cell lines. (A-H) Mutation frequencies of NOTCH1-4 (A) and proteins that are
well known in the pathology of cancer (B-E), as well as house-keeping proteins that do not have an established role in tumor formation (F-H).
Mutation frequencies are shown for both cancer cell lines and primary tumors for 12 different cell types, as indicated. In (I), the difference in
percentage (Δ%) between cell lines and primary tumors for each protein/protein family in (A-H), and for each cell type have been ranked and
plotted. Values have been normalized to the average coding region size of each protein/protein family (Δ%/10000 bp).
Mutvei et al. BMC Cancer  (2015) 15:311 Page 9 of 11tumor suppressors compared to corresponding primary
tumors. This notion holds true also for Notch receptors,
and to some extent Notch ligands, but not for the
house-keeping genes.
Discussion
There is an emerging view that deregulated Notch sig-
naling is linked to cancer and this notion receives sup-
port both from the identification of specific mutation
patterns in Notch receptors, as well as from numerous
studies reporting altered Notch signaling levels in a
broad set of tumor types. In keeping with a cell context-
specific signaling output, Notch can act as an oncogene
or tumor suppressor gene, depending on the tissue of
origin. These multi-faceted links between Notch and
cancer prompted us to address to what extent Notch
genes are mutated in established tumor cell lines, as
such information would be a valuable resource to better
understand Notch signaling and its role in the control of
cellular growth in vitro. An important conclusion from
our data is that the mutational frequency for the Notch
receptors was similar to that of the well-established on-
cogenes ErbB1-4 and the tumor suppressor genes
Patched1-2 and APC, whereas H/K/N Ras and p53, as
expected, showed considerably higher frequencies. Fur-
thermore, the frequency of Notch mutations was higher
in tumor cell lines when compared to primary tumors,
which was also the case for the majority of the other on-
cogenes and tumor suppressor genes, but not for a set
of house-keeping genes. Although mutations might be
more easily detectable in cell lines because of their
homogenous nature, the substantial increase in mutation
frequency argues that Notch mutations become enriched
in multiple tumor cell lines during in vitro culturing.
Notch mutations may thus confer a growth advantage
and could be considered to be driver mutations for
in vitro growth, although this remains to be functionally
tested in future studies. It should also be kept in mind
that accumulation of mutations in cell lines may not be
completely linked to growth advantages, as primary tu-
mors rarely are completely pure, but may be contami-
nated with stromal cells. Moreover, mutations in CCLE,
in contrast to TCGA, contains private germline variants
[43]. The hypothesis that at least some of the Notch mu-
tations may be driver mutations is of interest from a
therapeutic perspective. Considerable efforts are made to
develop novel therapies that blocks or ameliorates Notchsignaling, with several strategies currently being evalu-
ated in preclinical and clinical trials [6]. It would be in-
teresting to functionally test mutations identified in this
study, to learn if there are novel uncharacterized gain-
of-function mutations which could serve as future thera-
peutic targets.
The mutations in the Notch receptor genes were pre-
dominantly missense mutations, which is in keeping
with the overall mutation spectrum in tumors [1]. Gene
loss frequency for the Notch receptor genes was in con-
trast rather low. The Notch mutations were distributed
along the length of the four Notch receptor genes, a dis-
tribution also observed for NOTCH1 in a smaller breast
cancer data set [44]. In the EGF repeat domain at the
extracellular side, mutations were found across the ma-
jority of the EGF repeats, but none of the mutations led
to a gain or loss of a cysteine residue, which is the defin-
ing mutation for NOTCH3 in CADASIL [33]. CADASIL
NOTCH3 mutations are however not considered to pro-
vide a growth advantage, but rather to lead to degener-
ation of vascular smooth muscle cells. Interestingly, we
identified receptor-specific differences in the mutation
spectrum, in particular for the NRR region and the
PEST domain in the intracellular domains, where NRR
and PEST mutations were more prevalent in NOTCH1
and 2, as compared to NOTCH3 and 4. The receptor
bias for PEST mutations is interesting given the import-
ant role of the PEST domain in regulating the stability
of Notch ICD. NOTCH1 PEST domain mutations are
frequently observed in T-ALL, where they are gain-of-
function mutations leading to a more long-lived form of
NOTCH1 ICD [7,45]. When mutations were scored for
potential impact on protein function, with a subPSEC
score below −3, most NOTCH1 mutations clustered in
the ligand-binding region or in the ICD. Moreover, in
keeping with the tumor suppressor role of NOTCH1 in
skin [12], it is of note that melanoma cancer cell lines
contained the fewest NOTCH1 mutations and melan-
oma was also the only cell type that had a higher muta-
tion frequency in primary tumors compared to cell lines.
The catalog of Notch ICD mutations generated by our
analysis of the CCLE data base provides an opportunity
to functionally characterize the effects of these muta-
tions, for example with regard to alterations in signaling
strength [46], intracellular routing [47] or the ability to
intersect with other signaling mechanisms [6]. The
Notch ICD serves as an interaction hub for the cross-
Mutvei et al. BMC Cancer  (2015) 15:311 Page 10 of 11talk between Notch signaling and other signaling mecha-
nisms such as the cellular hypoxic response and the
BMP/TGF-beta signaling pathway, where Notch ICD in-
teracts with HIF and SMAD proteins, respectively (for
review see [5]). Notch also cross-talks with PI3K and
NF-kB signaling [4,48], and to learn if the mutations
affect these cross-talks is of interest from the perspective
of Notch therapy development.Conclusions
The mutation frequency of Notch receptor genes in
established tumor cell lines is similar to that of estab-
lished oncogenes and tumor suppressors. Moreover,
Notch mutations are found at a higher frequency in
tumor cell lines compared to primary tumors. This im-
plies that Notch mutations may be connected with a
growth advantage in vitro and thus may be considered
to be driver mutations in tumor cell lines.Additional files
Additional file 1: Figure S1. (A) The overall number of mutations per
cell line for the different cell types. (B-E) Lollipop plots to visualize
potential clustering of mutations for NOTCH1 (B), NOTCH2 (C), NOTCH3
(D) and NOTCH4 (E). The color of the pins denote the different mutation
types in the following way: black = indels, green =missense mutations,
red = truncating mutations (nonsense, nonstop, frameshift alterations and
splice site alterations), gray = other mutations. (F) The overall number of
the different types of mutations across the four Notch receptor genes.
LNR = Lin12-Notch repeats, ANK = ankyrin repeats, PEST = proline,
glutamic acid, serine and threonine rich domain. Figure S2. Mutations in
Notch ligands in the CCLE data set (A) Lollipop plots to visualize
mutations for JAG1, JAG2, DLL1 and DLL4. The color code of the pins is
explained in the legend of Supplementary Figure 1. MNNL = N-terminal
domain of Notch ligands, DSL = Delta-Serrate-LAG-2 domain (B) The
overall number of the different types of mutations across four of the
Notch ligand genes. The transmembrane domain is denoted by a vertical
bar. Figure S3. Notch receptors constitute mutational hot spots in
established cancer cell lines. (A-C) Mutation frequencies of Patched1-2
(A), Jagged1 and 2 (B), and Delta-like 1 and 4 (C). (D-E) The differences
in percentage (Δ%) between cell lines and primary tumors for each
protein/protein family in Figure 4A-H and Supplementary Figure 3A for
each cell type have been ranked and plotted (without normalization to
the average coding region size of each protein/protein family, which is
shown in Figure 4I).
Additional file 2: Data 1. Notch receptor and ligand mutations in
different cell lines, as specified in the CCLE-dataset.Abbreviations
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